Pipeline

Therapeutic Area
Area Project Category Indication Research Pre-clinical Phase I Phase II Phase III Remarks
Orphan Open
Innovation		 HL2356
(GX-H9)		 Biologic Growth Hormone Deficiency in Adults          
  • Collaborated with Genexine
  • TJ Biopharma: BLA submission to CFDA
Growth Hormone Deficiency in Pediatrics          
Orphan/ Metabolism Open
Innovation		 RZ358 Biologic Intravenous monoclonal antibody for Congenital Hyperinsulinism          
  • Rezolute: Licensor
  • Handok: Korea right for development and commercialization
  • RZ358 US FDA Orphan Drug Designation
RZ402 NCE
(New chemical entity)		 Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema          
Oncology Handok
R&D		 HD-NC003 NCE  PROTAC Solid cancer          
  • Collaborated with BNJ Biopharma
  • HD-NC004 Selected for the Ministry of Trade, Industry and Energy's Joint R&D Project of the Global Industrial Technology Cooperation Center (GITCC)
  • Selected for Presentation Abstract at AACR2025 in the US
HD-NC004          
Open
Innovation		 HD-B001A Biologic Solid cancer
(BTC)		          
  • ABL Bio: Licensor
  • Handok: Korea right, collaboration with Compass Therapeutics for global clinical trial phase 2/3 (Tovecimig meets primary endpoint in Phase 2/3 study)
SBP-101 NCE Melanoma, BTC, GBM          
  • SPARK Biopharma: Licensor
  • Handok: Korea right for development and commercialization
ABL111 Biologic Solid cancer          
  • ABL Bio: Licensor
  • Handok: Korea right for development and commercialization
ABL503          
  • ABL Bio: Licensor
  • Handok: Right of first negotiation for Korea
Digital Health
Digital Health Project Category Indication Discovery POC Pivotal Regulatory Commercial Remarks
CNS Open
Innovation		 WELT-I DTx Insomnia(Brand: SleepQ)          
  • Welt: Licensor
  • Handok: Korea right for development and commercialization
  • SleepQ Temporary Listing by the Health Insurance Review & Assessment Service
WELT-A DTx Alcoholism          
맨위로